Haloperidol decanoate in chronic schizophrenia: A study of 12 months with plasma levels

Altamura, Carlo; Colacurcio, F; Kauri, Massimo C.; Moro, A. R.; Novellis, Fedele De

doi:10.1016/0278-5846(90)90061-k

Cited by 17 publications

(3 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…When switching from oral to parenteral administration of the same antipsychotic (e.g., haloperidol), comparable plasma levels may not be reached. This can account for early relapse or poor response to a long-acting antipsychotic treatment (Altamura et al 1990). In addition plasma levels may be useful to predict and explain unwanted side effects of depot antipsychotics (Altamura et al 1985).…”

Section: Long-acting Depot Medicationmentioning

confidence: 99%

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 2: Long-term treatment of schizophrenia

Falkai

Wobrock

Lieberman

et al. 2006

The World Journal of Biological Psychiatry

201

View full text Add to dashboard Cite

These guidelines for the biological treatment of schizophrenia were developed by an international Task Force of the World Federation of Societies of Biological Psychiatry (WFSBP). The goal during the development of these guidelines was to review systematically all available evidence pertaining to the treatment of schizophrenia, and to reach a consensus on a series of practice recommendations that are clinically and scientifically meaningful based on the available evidence. These guidelines are intended for use by all physicians seeing and treating people with schizophrenia. The data used for developing these guidelines have been extracted primarily from various national treatment guidelines and panels for schizophrenia, as well as from meta-analyses, reviews and randomised clinical trials on the efficacy of pharmacological and other biological treatment interventions identified by a search of the MEDLINE database and Cochrane Library. The identified literature was evaluated with respect to the strength of evidence for its efficacy and then categorised into four levels of evidence (A Á/D). This second part of the guidelines covers the long-term treatment as well as the management of relevant side effects. These guidelines are primarily concerned with the biological treatment (including antipsychotic medication, other pharmacological treatment options, electroconvulsive therapy, adjunctive and novel therapeutic strategies) of adults suffering from schizophrenia.Key words: Schizophrenia, long-term treatment, evidence-based medicine, practice guidelines, biological treatment, antipsychotics EXECUTIVE SUMMARY OF RECOMMENDATIONS General recommendationsSpecific treatment strategies are required not only for patients suffering from acute schizophrenia, but also in the stabilisation and stable phase of the disease. The stabilisation period follows the acute phase and constitutes a time-limited transition to continuing treatment in the stable phase. The stable phase represents a prolonged period of treatment and rehabilitation during which symptoms are under adequate control and the focus is on improving functioning and recovery. The goals of long-term therapy have to be discussed with the patient on the background of adequately provided information and his personal goals in order to find common ground to encourage a long-term medication strategy (shared-decision making). In this regard a treatment plan must be formulated and implemented. During the stabilisation phase, the main goals of treatment are to facilitate continued reduction in symptoms, consolidate remission, and promote the process of recovery. The main goals of treatment during the stable phase are to ensure that symptom remission or control is sustained, that the patient is maintaining or improving the level of functioning and quality of life, to prevent relapse, and to ensure that monitoring for adverse treatment effects continues. The antipsychotic pharmacological therapy should be accompanied by psychosocial interventions. A number of psychosocial...

show abstract

Section: Long-acting Depot Medicationmentioning

confidence: 99%

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 2: Long-term treatment of schizophrenia

Falkai

Wobrock

Lieberman

et al. 2006

The World Journal of Biological Psychiatry

201

View full text Add to dashboard Cite

show abstract

“…Quando se muda da versão oral para a parenteral do mesmo antipsicótico (por exemplo, o haloperidol), ní-veis plasmáticos comparáveis podem não ser atingidos, podendo resultar na recaída precoce ou numa reposta precária ao tratamento antipsicótico de longa ação (Altamura et al, 1990). Além disso, os níveis plasmáticos podem ser úteis para prever e explicar efeitos colaterais indesejados dos antipsicóticos de depósito (Altamura et al, 1985).…”

Section: Medicação De Depósito Com Longa Açãounclassified

Diretrizes da Federação Mundial das Sociedades de Psiquiatria Biológica para o tratamento biológico da esquizofrenia. Parte 2: tratamento de longo prazo

Falkai¹,

Wobrock²,

Lieberman³

et al. 2006

Rev. psiquiatr. clín.

View full text Add to dashboard Cite

ResumoEstas diretrizes para o tratamento biológico da esquizofrenia foram desenvolvidas pela Força-Tarefa da Federação Mundial das Sociedades de Psiquiatria Biológica (World Federation of Societies of Biological Psychiatry, WFSBP). As metas fixadas durante o desenvolvimento destas diretrizes foi a revisão sistemática de todas as evidências disponíveis referentes ao tratamento da esquizofrenia, tanto no âmbito clínico como no científico, e o estabelecimento de um consenso sobre as principais recomendações para a prática psiquiátrica. Estas diretrizes são destinadas a todos os médicos que atendem e tratam de pacientes portadores de esquizofrenia. Os dados usados para desenvolver estas diretrizes foram extraídos primariamente de vários painéis e diretrizes nacionais para o tratamento da esquizofrenia, assim como de metanálises, revisões e estudos clínicos randomizados sobre a eficácia do tratamento farmacológico e de outras intervenções terapêuticas biológicas, identificadas por uma busca nas bases de dados MedLine e na Biblioteca Cochrane. A literatura identificada

show abstract

“…The pharmacokinetics of HLD has been evaluated and described by various investigators (Reyntijens et al, 1982;Altamura et al, 1990;Wiles et al, 1990). HLD is usually administered on a monthly or every four-week interval.…”

Section: Introductionmentioning

confidence: 99%

Disposition of haloperidol and reduced haloperidol plasma levels after single dose haloperidol decanoate administration

Chang

Juang

Lin

et al. 1995

Human Psychopharmacology

View full text Add to dashboard Cite

A single dose of haloperidol decanoate 100 mg was administered to 15 schizophrenic patients. Blood samples were obtained prior to injection, 1 h, 3 h, 6 h,'8 h, 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, one week, two weeks, three weeks and four weeks post-injection. Haloperidol and its reduced metabolite, reduced haloperidol, plasma levels were assayed by HPLC with electrochemical detection. The pharmacokinetic parameters of haloperidol were determined. The mean time of maximal (T,,,) plasma levels for haloperidol was 5.73 f 0.80 days. The haloperidol plasma levels showed a biexponential decline with an elimination half-life of 15.78 f 5.90 days. Reduced haloperidol was rapidly formed from the haloperidol. The T,,, of reduced haloperidol was 7.00 f 2-35 days. The mean ratio reduced haloperidolhaloperidol was 0.155 &-0.1 11. Since the T,,, occurs at approximately six days, a weekly loading dose of haloperidol decanoate is feasible during the transition from oral to depot therapy.KEY woms-Haloperidol decanoate, haloperidol and reduced haloperidol plasma levels.

show abstract

Haloperidol decanoate in chronic schizophrenia: A study of 12 months with plasma levels

Cited by 17 publications

References 14 publications

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 2: Long-term treatment of schizophrenia

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 2: Long-term treatment of schizophrenia

Diretrizes da Federação Mundial das Sociedades de Psiquiatria Biológica para o tratamento biológico da esquizofrenia. Parte 2: tratamento de longo prazo

Disposition of haloperidol and reduced haloperidol plasma levels after single dose haloperidol decanoate administration

Contact Info

Product

Resources

About